Breast cancer-specific survival in 6, 768 patients with lymph nodepositive (LN+) hormone receptor-positive (HR+) invasive breast cancer (BC) and 21-gene Recurrence Score® (RS) results in the SEER registries. (March 2017) - Shak, S.; Roberts, M.; Petkov, V.I.; Miller, D.P.; Howlader, N.; Cronin, K.; Penberthy, L.